# US 2019/0010126 A1 · Sulfonamide compounds and uses as tnap inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0010126 A1
- Document ID: US20190010126A1
- Status: Published application
- Kind: A1
- Application number: 15/888,736
- Filed: 2018-02-05
- Published: 2019-01-10
- Earliest claimed: 2012-02-22
- Assignees: Sanford-Burnham Medical Research Institute
- Applicants: Sanford-Burnham Medical Research Institute
- Inventors: Anthony B. PINKERTON; Russell DAHL; Nicholas D.P. COSFORD; Jose Luis MILLAN
- Web page: https://patentgrep.com/patent/US20190010126A1

## CPC

- C07D 213/76: to which a second hetero atom is attached (nitro radicals C07D213/61)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- C07D 213/79: Acids; Esters
- C07D 213/80: in position 3
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 231/42: Benzene-sulfonamido pyrazoles
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 239/69: Benzenesulfonamido-pyrimidines
- C07D 241/22: Benzenesulfonamido pyrazines
- C07D 261/16: Benzene-sulfonamido isoxazoles
- C07D 263/50: Benzene-sulfonamido oxazoles
- C07D 271/113: with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D 277/52: to sulfur atoms, e.g. sulfonamides
- C07D 285/135: Nitrogen atoms
- C07D 333/36: Nitrogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.

## Claims

### Claim 1

A method for treating pathological calcification or vascular calcification comprising administering a compound of Formula I, or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, metabolite, or N-oxide thereof:
wherein:
Y1 and Y2 are independently a bond or —N(R6)—, wherein at least one of Y1 and Y2 is —N(R6)—;
L1 and L2 are independently a bond or optionally substituted alkylene;
X1 is ═N— or ═C(R2)—;
X2 is ═N— or ═C(R3)—;
R1 and R4 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R2, R3, and R5 are independently selected from the group consisting of hydrogen, halogen, —CN, —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R6 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
R7 and R8 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted phenyl,
or R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino;
R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
A is selected from the group consisting of —C(O)—N(R7)—R8, —C(O)—O—R9, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein:
Y1 is a bond and Y2 is —N(R6)—;
X2 is ═C(R3)—;
L1 is a bond;
L2 is a bond; and
R6 is hydrogen as shown in Formula Ie:

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein X1 is ═C(R2)—.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein R4 is optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein R1 and R4 are independently selected from the group consisting of —F, —Cl, —Br, —CN, —OMe, and —OCF3.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein A is selected from:
wherein:
R12 and R13 are independently selected from the group consisting of hydrogen, halogen, —CN, —OH, —C(O)—N(R7)—R18, —C(O)—O—R19, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl,
wherein:
R17 and R18 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted phenyl, or R17 and R18 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino; and
R19 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
R15 is hydrogen or optionally substituted alkyl.

### Claim 20 (depends on 1)

The method of claim 1, wherein:
A is
wherein R12 and R13 are independently selected from the group consisting of hydrogen, —F, —CN, —OH, —OMe, and —C(O)—O-Me;
or A is —C(O)—O—R9;
or A is —C(O)—N(R7)—R8.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein: A is —C(O)—O—R9, wherein R9 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted phenyl.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 20)

The method of claim 20, wherein: A is —C(O)—N(R7)—(R8), wherein R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino.

### Claim 26 (depends on 25)

The method of claim 25, wherein the optionally substituted heterocycloamino is an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted morpholine, or an optionally substituted piperazine.

### Claim 27 (depends on 20)

The method of claim 20, wherein: A is —C(O)—N(R7)—(R8), wherein R7 is hydrogen and R8 is optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted phenyl.

### Claim 28

(canceled)

### Claim 29 (depends on 20)

The method of claim 20, wherein: A is —C(O)—N(R7)—(R8), wherein R7 and R8 are hydrogen.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the vascular calcification is an arterial calcification.

### Claim 34 (depends on 1)

The method of claim 1, wherein the vascular calcification is associated with diabetes mellitus I, diabetes mellitus II, idiopathic infantile arterial calcification (IIAC), Kawasaki disease, obesity, or increased age.

### Claim 35 (depends on 1)

The method of claim 1, wherein the vascular calcification is associated with chronic renal disease (chronic renal insufficiency), end-stage renal disease, or pre- or post-dialysis or uremia.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the pathological calcification is ankylosing spondylitis, tumoral calcinosis, fibrodysplasia ossificans progressiva, progressive osseous heteroplasia, pseudoxanthoma elasticum, ankylosis, osteoarthritis, general arterial calcification in infancy (GACI), arterial calcification due to deficiency of CD73 (ACDC), Keutel syndrome, peritoneal calcification, heterotopic calcification in amputees, tibial artery calcification, bone metastasis, prosthetic calcification, or Paget's disease of bone.

### Claim 38 (depends on 1)

The method of claim 1 wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, metabolite, or N-oxide thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the compound is:
or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, metabolite, or N-oxide thereof.
